HS-20108 / Jiangsu Hansoh Pharma - LARVOL DELTA

Phase 1 Study of HS-20108, a SEZ6 Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors (ESMO 2026) - No abstract available

ADC • Clinical • Metastases • P1 data • Oncology • Solid Tumor • SEZ6

A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=502 | Recruiting | Sponsor: Hansoh BioMedical R&D Company | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2027 ➔ Feb 2029 | Trial primary completion date: Oct 2027 ➔ Aug 2028

Enrollment open • Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase I Study of HS-20108 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=502 | Not yet recruiting | Sponsor: Hansoh BioMedical R&D Company

New P1 trial • Lung Cancer • Small Cell Lung Cancer • Solid Tumor

THE CLINICAL TRIAL APPROVAL FOR HS-20108 FOR INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION (HKEXnews) - "The board of directors (the 'Board') of Hansoh Pharmaceutical Group Company Limited (the 'Company' and together with its subsidiaries, the 'Group') is pleased to announce that, the innovative drug HS-20108 for injection, self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China recently, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors."

New trial • Neuroendocrine Tumor • Small Cell Lung Cancer